<DOC>
	<DOCNO>NCT00706914</DOCNO>
	<brief_summary>This exploratory study compare efficacy fixed-dose combination ( FDC ) aclidinium bromide formoterol fumarate daily morning placebo even vs. FDC daily morning formoterol fumarate even vs. formoterol fumarate twice daily . The study assess pulmonary function symptom patient moderate severe COPD .</brief_summary>
	<brief_title>Comparison Aclidinium Bromide Formoterol Fumarate Patients With Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Moderate severe COPD Smoking history great equal 10 packyears Diagnosis stable moderate severe COPD define GOLD Guidelines Postbronchodilator FEV1 30 % 79 % predicted value , inclusive Postbronchodilator FEV1/FVC ratio &lt; 0.70 History presence asthma , allergic rhinitis , exerciseinduced bronchospasm Hospitalization acute COPD exacerbation 3 month prior study entry Respiratory tract infection ( include upper respiratory tract ) COPD exacerbation 6 week prior study entry Eosinophil count least 600 cells/mm3 Long term oxygen therapy &gt; 15 hour day</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Airflow Obstruction , Chronic</keyword>
	<keyword>Chronic Airflow Obstruction</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Chronic Obstructive Airway Disease</keyword>
	<keyword>Chronic Obstructive Lung Disease</keyword>
	<keyword>COPD</keyword>
	<keyword>COAD</keyword>
</DOC>